POPULARITY
7 episodes with drug therapy
3 episodes with drug therapy
2 episodes with drug therapy
2 episodes with drug therapy
2 episodes with drug therapy
2 episodes with drug therapy
5 episodes with drug therapy
2 episodes with drug therapy
2 episodes with drug therapy
Dr. John Fleetham chats with Dr. Hedner and Dr. Schmickl about their articles “A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea" and “Drug Therapy for Obstructive Sleep Apnea: Are We There Yet?”
Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep disorders, and cognitive dysfunction, there are no good diagnostics to identify DLB and effective treatments. Cognition Therapeutics' lead drug candidate, an oral treatment, has shown promise in protecting neurons from the toxic effects of the pathological proteins involved in Alzheimer's and DLB. Lisa explains, "This company started in 2007, so we've had a long number of years to burnish our mission. One of the things we say is we're the beginning of the end of neurologic disorders and the start of hope for an improved future for patients. So Alzheimer's disease, in particular, has been long studied with little success, and in the last few years, we've seen some successes with monoclonal antibodies. There are a number of other approaches in clinical trials, but we have recently generated very positive data in two different trials with an oral once-a-day drug." Tony elaborates, "Lewy body dementia or dementia with Lewy bodies is a disease very much related to Parkinson's disease that's believed to be, in part, caused by pathological levels of a certain protein called alpha synuclein and particularly small oligomers of misfolded alpha synuclein." "And in Alzheimer's disease, this is largely a cognitive memory disorder as it presents. So, those two diseases are very different. Now, the idea of treating them with a single drug is somewhat unique to what we have here at Cognition Therapeutics. So our company started around the idea of developing therapies for Alzheimer's disease, and our lead molecule CT1812 or zervimesine was developed out of a screening assay where we were looking for molecules that could protect neurons or brain cells from the toxicities of this pathological amyloid protein. So, we identified CT1812 and have been developing it." #CognitionTherapeutics #BrainHealth #DementiaCare #LewyStrong #Livingwithlewy #Alzheimers #EndAlz #Alzheimersdisease #DLBAwareness #NeurodegenerativeDisease #Dementia #DementiaWithLewyBodies cogrx.com Download the transcript here
Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep disorders, and cognitive dysfunction, there are no good diagnostics to identify DLB and effective treatments. Cognition Therapeutics' lead drug candidate, an oral treatment, has shown promise in protecting neurons from the toxic effects of the pathological proteins involved in Alzheimer's and DLB. Lisa explains, "This company started in 2007, so we've had a long number of years to burnish our mission. One of the things we say is we're the beginning of the end of neurologic disorders and the start of hope for an improved future for patients. So Alzheimer's disease, in particular, has been long studied with little success, and in the last few years, we've seen some successes with monoclonal antibodies. There are a number of other approaches in clinical trials, but we have recently generated very positive data in two different trials with an oral once-a-day drug." Tony elaborates, "Lewy body dementia or dementia with Lewy bodies is a disease very much related to Parkinson's disease that's believed to be, in part, caused by pathological levels of a certain protein called alpha synuclein and particularly small oligomers of misfolded alpha synuclein." "And in Alzheimer's disease, this is largely a cognitive memory disorder as it presents. So, those two diseases are very different. Now, the idea of treating them with a single drug is somewhat unique to what we have here at Cognition Therapeutics. So our company started around the idea of developing therapies for Alzheimer's disease, and our lead molecule CT1812 or zervimesine was developed out of a screening assay where we were looking for molecules that could protect neurons or brain cells from the toxicities of this pathological amyloid protein. So, we identified CT1812 and have been developing it." #CognitionTherapeutics #BrainHealth #DementiaCare #LewyStrong #Livingwithlewy #Alzheimers #EndAlz #Alzheimersdisease #DLBAwareness #NeurodegenerativeDisease #Dementia #DementiaWithLewyBodies cogrx.com Listen to the podcast here
View Activity Information…
Researchers Evaluate Drug Therapy for Obesity-Related Sleep Apnea By Today's RDH Research Original article published on Today's RDH: https://www.todaysrdh.com/researchers-evaluate-drug-therapy-for-obesity-related-sleep-apnea/ Need CE? Start earning CE credits today at https://rdh.tv/ce Get daily dental hygiene articles at https://www.todaysrdh.com Follow Today's RDH on Facebook: https://www.facebook.com/TodaysRDH/ Follow Kara RDH on Facebook: https://www.facebook.com/DentalHygieneKaraRDH/ Follow Kara RDH on Instagram: https://www.instagram.com/kara_rdh/
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during HIV Drug Therapy, Glasgow 2024.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYAnton Pozniak, MD, FRCPConsultant PhysicianChelsea and Westminster Hospital London UKThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-hiv-drug-therapy-glasgow-2024-1
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during HIV Drug Therapy, Glasgow 2024.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYAnton Pozniak, MD, FRCPConsultant PhysicianChelsea and Westminster Hospital London UKThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-hiv-drug-therapy-glasgow-2024-1
I got the opportunity to talk to Dr. Joseph Schlessinger, professor at Yale and cofounder of SUGEN and Plexxikon. We talked about his experience as a captain the Israeli Army during the Six Day War and the Yom Kippur War and how it affected his career as a scientist and entrepreneur. We also talked about the companies he formed and his research on tyrosine kinase. ---------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoat Newsly: https://newsly.me promo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.com promo code: DGDubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips: https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com
Gregg Klang, Femtech founder of CERN Corporation, discusses the development of a microbiocidal light device for yeast and bacterial vaginosis treatment. The device offers an alternative to drug-based therapies, catering to those who prefer non-medication options. Greg explains the status of development, including human trials, in vitro and ex vivo testing, and animal testing for safety. Tune in to learn more about his journey into women's health tech innovation with CERN Corporation.Timestamps(01:20) CERN Corporation was founded to develop a non-drug therapy for yeast and bacterial vaginosis, targeting those for whom drug-based therapies are not effective or desired.(10:23) The CERN device uses microbiocidal light therapy to target key pathogens associated with yeast and bacterial vaginosis, providing a non-drug treatment option.(16:39) The CERN device is designed to accommodate different sizes to ensure comfort and effectiveness for women with varying pelvic floor conditions, including hypertonicity.(32:26) Physicians are impressed by the CERN device's approach and potential benefits for patients, expressing interest in its availability and integration into their practices.(44:24) The founder of CERN Corporation emphasizes the importance of the team's support and expertise in driving the development and success of the non-drug therapy device.Host BioThis podcast is hosted by Sheree Dibiase, PT ICLM. She is a nationally recognized women's health physical therapist who owns seven private clinics — one of the biggest networks in the US. She has spent 30+ years practicing in the oncology, pelvic floor, and prenatal postpartum healthcare spaces. She was also a professor for seven years a Loma Linda University where she taught kinesiology. Brought to you by...https://lakecitypt.com/ - Women's health physical therapy. https://pelvicfloorpro.com/ - Pelvic floor physical therapy from home. KeywordsFemtech, Women's Health, Pelvic Floor, Breast Cancer, Prenatal & postpartum
Following our previous podcast on the non-pharmacological management of Diabetes, this episode delves into a detailed review of drug therapy in diabetes. Brig (Dr) J Muthukrishnan the host, an eminent endocrinologist himself indulges in this fascinating and very useful discussion with Wg Cdr (Dr) Sandeep Kumar, an endocrinologist of national repute.
Commentary by Dr. Valentin Fuster
Commentary by Dr. Valentin Fuster
This conversation explores why proper use of non-invasive tests (NITs) will play a pivotal role in increasing the number of patients diagnosed and treated for MASH. It becomes particularly pivotal if, as expected, the first MASH drug is approved later this month. Roger Green starts this conversation by describing why he considers NIT use and adoption one of the two pivotal patient treatment issues for 2024. Jörn Schattenberg notes that he has not received any referrals from PCPs or endocrinology based on elevated FIB-4, which would happen if enough front-line treaters were adopting the new clinical care pathways. Educational efforts have begun, but do not seem to be changing behavior yet. As Jörn puts it, "We're still preaching, and I haven't seen it in much activity."Naim Alkhouri states that his experience is the same as Jörn's. He reminds us that we covered some of these issues in a 2023 end-of-year conversation (S4 E50.3). He reiterates his concern with FIB-4 as a standalone first-line test and states his preference for combining it with an in-office scan. He comments that at the recent Desert Liver Conference, four companies displayed these devices, each with a different price point and convenience factor. Ian Rowe describes the British experience as being different: "every patient with elevated ALT in the context of metabolic risk factors has a FIB-4 and now has a FibroScan." His biggest concern is that tests are insufficiently precise. If we have top-end and bottom-end cutoffs, he fears, "you're going to end up excluding a lot of patients who would be potentially eligible for treatment."
It depends… on the prison…Mostly the jail makes the people worse…Consider that more than 50% of the prisoner have mental and physical illnesses, are addicted,have traumatic Childhood, and all kind of madness… In the previous Communist Countries like Burma, China, Vietnam… didn't exist a jail the only one penalty was death penalty…The person who was criminally engaged got 2 times warnings and then he got the death penalty…Did this death penalty for every crime help to keep the crime at an absolute minimum?Yes… Would this work also today?In Singapore, Indonesia, Malaysia is a death penalty for owning, selling, and taking drugs… In these countries, the crime connected with and for getting drugs is at an absolute minimum.In Singapore or Malaysia is every couple of years only one death execution for drugs… Think over how huge is a drug-crime everywhere else.Addicted people have to do crimes to afford their drugs…If we see that over 50% of the prisoner have a mental disease, instead to do Therapy. -Why?Most of all people would not do any therapy for resolving their mental diseases.Even the best Therapies will not work if the patients are not surrendering to 100% to this therapy!If you do not want to change, therapy cannot help!For instance, drug addiction…My friend was addicted; is today a therapist for drugs and is working at the biggest Drug Therapy center in Bremen.After 6 weeks to 9 months staying in this addiction hospital, the success quote for their paid addiction therapy: 50% of the patients are cured or for at least 3 years free of addiction…25% are taking suicide,25% are not cured. Most of all jails are a violation of human rights… The staff of the prison is well known for their violence; - this means: body and mental abuse, rapping, killing,corruption, drug trading … Who is more criminal the prisoner or the staff of the prison? The prisoner cannot trust any person, is getting harder and feels less, is getting more violent,learns bad behavior,is isolated and,Is harder to integrate into society afterward… What speaks for the prison?The prison penalty prevents crime.The criminal people cannot harm people when they are in the prison… During prison time, Prisoners should be trained and educated, so that they can work and learn to use their time wisely.The prisoner should also work…There should be a religious service to make the Prisoner better.Therapy, meditation, and yoga should be in every prison. My Video: Does the jail make us better? https://youtu.be/TkP61GsfdfkMy Audio: https://divinesuccess.net/wp-content/uploads/2021/Podcast2/Does-the-jail-make-us-better.mp3
Contact Me Here - ❤️ https://bit.ly/m/TammyCuthbertGarcia ❤️ Today on Naturally Inspired Radio Israeli biotech launched A.I. programmable drug therapy, Bret Weinstein gets emotional about the Israeli war, Illinois state court passes that employers can now make employees choose between shots and jobs, vaccinated are actually sicker than unvaccinated says Dr Clare Craig, organ meats and how they are incredible for your health, David goggins on purpose. Tune In to Naturally Inspired Radio Live… Mon-Thu, 3pm (MDT) on 1360am KHNC in Colorado, at https://bit.ly/naturallyinspiredradio Text in your comments/questions to 877-536-1360 and enter to win our weekly giveaway Please Like
Israeli biotech startup Mana.bio has been planning to launch its programmable drug treatment solution for months, and decided to forge ahead in spite of the attacks that happened this past weekend in the country.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.18.549357v1?rss=1 Authors: Chen, H.-J. C., Yang, A., Mazzaferro, S., Mali, I., Cahn, O., Kentistou, K., Rowley, C., Stewart, N., Seah, J. W. E., Pisupati, V., Kirwan, P., Aggarwal, S., Toyohara, T., Florido, M. H. C., Cowan, C. A., Quambusch, L., Hyvonen, M., Livesey, M. R., Perry, J. R. B., Marioni, J. C., Merkle, F. T. Abstract: Obesity substantially increases the risk of type 2 diabetes, cardiovascular disease, and other diseases, making it a leading preventable cause of death in developed countries. It has a strong genetic basis, with obesity-associated genetic variants preferentially acting in the brain. This includes the hypothalamic pro-opiomelanocortin (POMC) neurons that inhibit food intake and are stimulated by drugs that agonise glucagon-like 1 peptide receptor (GLP1R) including Semaglutide (Ozempic/Wegovy). We therefore hypothesised that drugs which selectively activate human POMC neurons would suppress appetite and promote weight loss, and that focusing on drugs already approved for use would facilitate rapid clinical translation. We therefore generated POMC neurons from human pluripotent stem cells (hPSCs) and identified enriched genes that were genetically associated with obesity and targeted by approved drugs. We found that human POMC neurons are enriched in GLP1R, reliably activated by Semaglutide, and their responses are further increased by co-administration of Ceritinib, an FDA-approved drug potently and selectively inhibiting anaplastic lymphoma kinase (ALK). Ceritinib reduced food intake and body weight in obese but not lean mice, and upregulated the expression of GLP1R in the mouse hypothalamus and hPSC-derived human hypothalamic neurons. These studies reveal a new potential therapeutic strategy for reducing food intake and body weight, and demonstrate the utility of hPSC-derived hypothalamic neurons for drug discovery. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Bob Harrington interviews Jag Singh about the COVID journey that led to his book, Future Care: Sensors, Artificial Intelligence, and the Reinvention of Medicine. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit: https://www.medscape.com/author/bob-harrington Future Care: Sensors, Artificial Intelligence, and the Reinvention of Medicine. https://www.jagsinghmd.com/book COVID-19 Hits Physician Couple: Dramatically Different Responses https://www.medscape.com/viewarticle/928530 Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study https://doi.org/10.1016/j.ijcard.2021.01.002 The Care of the Patient https://doi.org/10.1001/jama.1927.02680380001001 Advancements and future directions in the teamwork, targets, technology, and tight control-the 4T study: improving clinical outcomes in newly diagnosed pediatric type 1 diabetes https://doi.org/10.1097/mop.0000000000001140 Social determinants of telemedicine utilization in ambulatory cardiovascular patients during the COVID-19 pandemic https://doi.org/10.1093/ehjdh/ztab039 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact: news@medscape.net
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA (Twitter: @sasoefje) describes the relationship between value and quality, defines quality and how quality measures will impact healthcare in the coming years, and demonstrates how organizations may use quality measures to improve value. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter! You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
(4:00) - Wearable patch can painlessly deliver drugs through the skinThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn about how wearable technology has been making its way into the medical industry.
We the Scientists: How a Daring Team of Parents and Doctors Forged a New Path for MedicinePulitzer Prize winning Wall Street Reporter Amy Marcus, in her new book We the Scientists, discusses a rare disease often likened to Children's Alzheimer's with BrainStorm Host Meryl Comer. Not only are the patients young, but their parents are desperate to help scientists find a drug to slow disease progression to extend their lives. Most children, born seemingly normal, rarely live beyond the age of 20. The common thread is advancing the science with new pathways for treating disease and conducting research. In the process to accelerate new drug development, science may be forever changed. Listen to part 2 of the interview with Amy Dockser Marcus and hear her thoughts on if this new collaborative research model could work for elderly populations with long-term chronic diseases like Alzheimer's.This episode is sponsored by Genentech and Eisai.If you have recommendations for topics or guests, email us at BrainStorm@usagainstalzheimers.org. To learn more go to: https://www.usagainstalzheimers.org/Support the show
John Mandrola, MD discusses early vs delayed AF ablation, a report on a devastating complication of AF ablation, and a potential crosswind for a major therapeutic fashion in electrophysiology. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Early Vs Delayed Ablation - Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences https://doi.org/10.1093/eurheartj/ehad247 - Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation https://www.ahajournals.org/doi/full/10.1161/CIRCEP.119.008128 - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa2029980 - Progression of Atrial Fibrillation after Cryoablation or Drug Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa2212540 II Atrial-Esophageal Fistula CT and Surgery Best Diagnose and Manage Esophageal Fistula https://www.medscape.com/viewarticle/990933 - A worldwide survey on incidence, management and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: The POTTER-AF study https://doi.org/10.1093/eurheartj/ehad250 - Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial https://doi.org/10.1093/europace/euaa209 - Temperature monitoring and temperature-driven irrigated radiofrequency energy titration do not prevent thermally induced esophageal lesions in pulmonary vein isolation: A randomized study controlled by esophagoscopy before and after catheter ablation https://doi.org/10.1016/j.hrthm.2021.02.003 III High-Power Short-Duration Ablation Short, High-Power Ablation on Par With Standard AF Ablation https://www.medscape.com/viewarticle/972087 - Power-Fast Trial https://clinicaltrials.gov/ct2/show/NCT04153747 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net
Renewed interest in the potential benefits of psychedelic treatments has led to an upsurge in research. Is the first FDA approval of a psychedelic for therapeutic use on the horizon? On this episode, Epstein Becker Green attorneys Delia Deschaine, Lisa Gora, and Jessika Tuazon examine the history of psychedelic substances in the United States and discuss the evolving legal and regulatory considerations impacting the development, approval, distribution, and use of psychedelic therapies in the United States. Visit our site for related resources and email contact information: https://www.ebglaw.com/dhc62. Subscribe for email notifications: https://www.ebglaw.com/subscribe. Visit: http://diagnosinghealthcare.com. The EMPLOYMENT LAW THIS WEEK® and DIAGNOSING HEALTH CARE podcasts are presented by Epstein Becker & Green, P.C. All rights are reserved. This audio recording includes information about legal issues and legal developments. Such materials are for informational purposes only and may not reflect the most current legal developments. These informational materials are not intended, and should not be taken, as legal advice on any particular set of facts or circumstances, and these materials are not a substitute for the advice of competent counsel. The content reflects the personal views and opinions of the participants. No attorney-client relationship has been created by this audio recording. This audio recording may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules. The determination of the need for legal services and the choice of a lawyer are extremely important decisions and should not be based solely upon advertisements or self-proclaimed expertise. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers.
Dr. Centor discusses the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes with Drs. Neda Laiteerapong and Aaron Winn.
AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Pushback on PROMINENT Zimerman Thread: https://twitter.com/AndreZimerman/status/1593019800036708353 II. IRONMAN IRONMAN Galvanizes Case for IV Iron Repletion in Heart Failure https://www.medscape.com/viewarticle/984030 Is Iron Replacement in Heart Failure Worth the Trouble? https://www.medscape.com/viewarticle/983622 - Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial https://doi.org/10.1016/S0140-6736(22)02083-9 III. ECMO-CS Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS https://www.medscape.com/viewarticle/983618 - Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949 - Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.118.004905 IV. CTS-AMI Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI https://www.medscape.com/viewarticle/983619 V. PROGRESSIVE AF First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy https://www.medscape.com/viewarticle/983882 Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview https://www.medscape.com/viewarticle/983474 - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa2029980 - Progression of Atrial Fibrillation after Cryoablation or Drug Therapy https://www.nejm.org/doi/10.1056/NEJMoa2212540 - Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders https://pubmed.ncbi.nlm.nih.gov/31779791/ You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net
Better Edge : A Northwestern Medicine podcast for physicians
Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome caused by mutations in the VHL gene. These mutations predispose patients to the development of cysts and tumors in several systems and organs, including the central nervous system, retina, kidneys, pancreas, adrenal glands and reproductive organs. VHL is a complex disease that requires specialized advanced treatment from a multidisciplinary team of specialists.In this Better Edge podcast episode, the following experts from the Northwestern Medicine Von Hippel-Lindau Disease Program discuss VHL and the clinical management for this patient population: Rimas V. Lukas, MD, Associate Professor of Neuro-Oncology; Niraj K. Shenoy, MD, PhD, MS, Associate Professor of Hematology/Oncology and of Pathology; and Brittany M. Szymaniak, PhD, CGC, Instructor of Urology. They share a recent Northwestern Medicine study published in Neuro-Oncology that examined belzutifan, the first approved HIF-2α inhibitor, in VHL-associated tumors.
A new meta-analysis of 28 studies showed Yoga was associated with the largest mean reduction in HbA1c at 1%, followed by qigong at 0.66% and mindfulness-based stress reduction at 0.48%.Reference: Sanogo F, et al. J Integr Complement Med. 2022;doi:10.1089/jicm.2022.0586VISIT OUR STOREStore: https://www.selfelements.comFOLLOW USwww.selfprinciple.orgwww. youtube.com/selfprinciplewww.youtube.com/plantbasedkidneyhealthwww.instagram.com/seanhashmimd
With Federico Guerra (Host), Ospedali Riuniti di Ancona - Italy, Rodrigue Garcia (Host), University hospital of Poitiers & John Camm (Host), United Kingdom of Great Britain and Northern Ireland This podcast tackles antiarrhythmic drugs in the setting of atrial fibrillation ablation management
This week on Pharm5: Polio in the US COVID vaccines linked to fewer CV events Vancomycin AUC vs. target troughs CMS Star Ratings 2022 Payment model is needed for Paxlovid prescribing Use APhA's pre-written, editable letter to advocate for pharmacist reimbursement for Paxlovid prescribing: https://bit.ly/3cKwm0O References: Meko H. First polio case in nearly a decade is detected in New York State. The New York Times. https://nyti.ms/3JbGLid. Published July 21, 2022. Accessed July 28, 2022. Polio vaccine effectiveness and duration of protection. Centers for Disease Control and Prevention. https://bit.ly/3JhiIyy. Published May 4, 2018. Accessed July 28, 2022. Kim Y-E, Huh K, Park Y-J, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. July 2022. doi:10.1001/jama.2022.12992 Abdelmessih E, Patel N, Vekaria J, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic Review and meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. July 2022. doi:10.1002/phar.2722 Chung D, Efta J, Brunsman A, et al. Evaluation of pharmacist time dedicated to vancomycin dosing in adult patients using a 24-hour AUC nomogram or Trough Monitoring Approach: A time motion study. American Journal of Health-System Pharmacy. 2022;79(14):1173-1179. doi:10.1093/ajhp/zxac094 Press release CMS releases 2022 Medicare Advantage and Part D star ratings to help Medicare beneficiaries compare plans. CMS. https://go.cms.gov/3oEzpKM. Accessed July 28, 2022. Emergency action is necessary to provide payment for pharmacist prescribing of Paxlovid. OneClickPolitics. https://bit.ly/3cKwm0O. Accessed July 28, 2022.
Atropine is what we call an anticholinergic drug, which means that it blocks acetylcholine. And when you block acetylcholine, it can cause temporary paralysis in the focusing system of the eye and it also dilates the pupil. So this particular technique is used by some eye doctors in low doses, to see if you can slow down school-aged myopia. My feeling is that Atropine therapy is really another symptomatic approach. It's not really getting to the cause of what myopia really is. So let's talk about the cause of myopia. And then I can offer some protocols that maybe go a little deeper than just treating the symptom. Enjoy the show.
A visit to the therapeutical centre Manternach, a centre for drug addictions that has recently presented their child-parent program where parents of young children receive addiction therapy together with their children.
Can a chemical found in citrus fruit curb cancer and save lives through early detection? Today on the show, we'll talk about the possibilities with Dr. David Suhy, Cofounder and Chief Medical Officer of Earli. Earli was founded with the mission to make cancer a benign experience by catching and curing it early. According the the American Cancer Society, 40% of people will be diagnosed with cancer at some point in their lifetime. And a third will die from it. What if there was a way to detect and confirm the presence of cancer by inducing synthetic biomarkers? You could catch cancer when it's most treatable and save countless lives. Learn more about this exciting technology and get inspired by David's insights. About David SuhyDr. David Suhy is the Chief Scientific Officer and Cofounder of Earli. He is a gene therapy expert, experienced in bio ventures both private and public. He has led gene therapy ideas from inception through Phase 2 clinical trials, and is recognized as a leader that science teams love to work with.Before Earli, he was the CSO at Benitec Biopharma where he oversaw development paths for products in or near term clinical studies, including Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC), and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first non-withdrawable, systemic RNAi compound used clinically in human subjects. He previously held scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara and PPD. He earned his PhD in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed his post doctoral training at Stanford University.He's a father to three teenagers, and he loves making pizza in his large wood-fired oven in his backyard. David is married to a neuroscientist, Dr. Joyce Suhy, who knows the risks of science, and is convinced that with David's passion, Earli will accomplish its purpose.About EarliEarli was founded in June of 2018 by Dr. Sam Gambhir, Cyriac Roeding and Dr. David Suhy. Earli is developing a technique, originally from Stanford University, to trigger the production of synthetic biomarkers as a means to detect, target and destroy cancer cells. Earli is currently enrolling for their clinical trial in Australia. LinksDavid Suhy | LinkedIn:https://www.linkedin.com/in/davidsuhyEarli:https://www.earli.comEarli Clinical Trial News:https://bit.ly/3A3bQ53Sam Gambhir | Wikipedia:https://en.wikipedia.org/wiki/Sanjiv_Sam_GambhirQualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
Commentary by Dr. Valentin Fuster
Healing with Natural Remedies and Frequencies vs Drug Therapy Dr. Smith Live 68th Episode Topics: Deaths due to prescription drugs now #1 cause of death Six primary areas to evaluate to reduce pain and illnesses Natural, noninvasive remedies to resolve pain Why the Biophoton System represents a major breakthrough in medical technology in the treatment of all medical maladies
Commentary by Dr. Valentin Fuster
In previous episodes, we've discussed the health consequences of obesity, its lifestyle modifications, and surgical options to counter this medical condition The primary job of every physician is to enable patients to have quality of life and low mortality. Lifestyle modification and healthy eating habits are not enough to help you lose weight. You should know that there are medications taken in conjunction with obesity treatment and they can also be linked to different comorbidities like osteoarthritis, PCOS, hypertension, diabetes, and sleep apnea that will most likely put you at life-threatening risk.If you are among countless others who have been struggling with obesity or if you know someone who needs help battling it, this episode cant help, guide and inform you on certain medications to choose fromToday's episode features Dr. Marilyn McGowan who graciously discusses the drug therapies for obesity that work to decrease appetite, slow down the digestion, help the pancreas work better, and many other benefits. We discuss the different medications and go further into their generic names, side effects, and price point. Listen in to know which drug therapy fits you best.Before taking any of the medications discussed, make sure that you consult with your doctor first and be knowledgeable about their contraindications and side effects. Let's jump right into Episode 33!Memorable Quotes:Persevere to achieve what you want because it really would improve the quality of life and will prevent all other consequences of obesity. - Dr. Julieta GabiolaThe safest, most tolerated, and best obesity medication for you is the one prescribed by your doctor. - Dr. Marilyn McGowanWe can do all the medications in the world, but it needs to be working very closely with diet, exercise, and lifestyle modification. - Dr. Marilyn McGowanWork with your doctor to know what medication really fits you. - Dr. Marilyn McGowanAbout the Guests:Dr. Marilyn McGowan is a 2nd-year Internal Medicine Resident at Stanford University. She is interested in primary care, particularly the treatment of chronic diseases, and in helping her patients achieve their health goals. Her hobbies are playing music, getting outside, or visiting her family on their farm in Northern California. About the Host:Dr. Jette Gabiola is a Clinical Professor of Medicine at Stanford University and the President & CEO of ABCs for Global Health. Click here for her full profile or read her full interview here. See acast.com/privacy for privacy and opt-out information.
Here are the things to expect in the episode:The teamwork of health professionals is the key to better cancer care.Effective communication skills will build a trust relationship between the patient and the health care team!How targeted therapies are used to treat cancer?Cancer research breakthrough that will change cancer treatment!And much more! The Stage of Change conference will be on September 15, 2022, at the Legacy Castle in Pompton, Plains, New Jersey. Get your tickets and find out more on the website https://www.lesliesweek.org/ About Samantha:PharmD - Recent PharmD graduate currently completing a pharmacy fellowship in Global Oncology Medical Affairs. Connect with Dr. Samantha Wilusz!Email: samantha.eagen@yahoo.comLinkedIn: https://www.linkedin.com/in/samantha-wilusz-0b53b872/ Connect with Kamie Lehmann!Website: https://www.kamielehmann.com/Facebook: https://www.facebook.com/kamie.lehmann.1LinkedIn: https://www.linkedin.com/in/kamie-lehmann-04683473
Commentary by Dr. Valentin Fuster
Susan Christo, Doherty Institute, discusses new research findings in the area of tissue-resident memory cells; and Megan Maher and Christopher McDevitt, also from the Doherty Institute, talk about research into pneumonia and a new drug therapy; then, Michael Ibbotson, Australian College of Optometry, discusses research into future epilepsy therapy involving tiny carbon electrode brain implants. And in weekly science news, the team discusses new findings on woolly mammoth's lifetime travels, risks for coyotes scavenging mountain lion's leftovers, and the significance of eye contact during conversations. With presenters Dr. Shane, Dr. Chris KP, Dr. Jen and Dr. Euan.Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-Go
Doug and Kelly spoke about the new breakthrough of mental health treatment. Right now we are in the midst of COVID - 19 pandemic, worries, anxieties and sleepless causes of overthinking have a huge factor on our mental health. There are Three Waves of Modern Mental Health Treatment: Psychotherapy, next is Drug Therapy and Finally this episode focuses on Wearable Device Treatment. It can be a Surgical or Non Surgical method. But most people prefer non surgical methods because of its conveniences. Kelly introduce us the wearable device from Fisher Wallace Laboratories, Fisher Wallace Stimulator. Learn more at https://www.fisherwallace.com (https://www.fisherwallace.com) Doug's business specializes in partnering with companies and non-profits to capture overhead cost savings without layoffs to fund growth and strengthen financial results. You can find the audio podcast feed at https://www.TerminalValuePodcast.com (www.TerminalValuePodcast.com) You can find the video podcast feed at https://www.youtube.com/channel/UCV5a4QbT-dXhpgb-8HJHdGg (www.youtube.com/channel/UCV5a4QbT-dXhpgb-8HJHdGg) Schedule time with Doug to talk about your business at https://www.MeetDoug.Biz (www.MeetDoug.Biz)
The COVID-19 surge, vaccine-induced myocarditis, Heart Rhythm news, the state of medical evidence, and doctors in unions are discussed by John Mandrola, MD, in this week's podcast. https://www.medscape.com/twic 1- COVID-19 Texas COVID-19 Wave Is Climbing More Steeply Than Past Waves https://www.medscape.com/viewarticle/956104 White House Says US Can Provide COVID-19 Boosters if Needed https://www.medscape.com/viewarticle/956016 2- Vaccine-Myocarditis Myocarditis Tied to COVID-19 Shots More Common Than Reported? https://www.medscape.com/viewarticle/956089 3- Heart Rhythm News The Three Big Stories from the Heart Rhythm Society's 2021 Meeting https://www.medscape.com/viewarticle/955989 4- Medical Evidence Despite Retraction, Study Using Fraudulent Surgisphere Data Still Cited https://www.medscape.com/viewarticle/956090 Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2782460 5- Doctors in Unions? Physicians Need to Unionize Now https://www.medscape.com/viewarticle/955888 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net
Genetic variation is one of the reasons people differ in their response to medicines. Understanding that variation can inform more refined choices of drugs and doses – ultimately preventing undesired side effects. Join us as we discuss past, present and future of pharmacogenomics with Uppsala Monitoring Centre's Qun-Ying Yue.Tune in to find out:How genetic biomarkers can guide medicine use and dosing recommendationsWhat we need to effectively implement genetic-based prescribing in clinical practiceHow increasing diversity in clinical trials can aid pharmacogenomics research Want to know more?Here are a few resources to get you started:SWEDEGENE is a Swedish nation-wide DNA sample collection established to facilitate pharmacogenomic studies of serious adverse drug reactions.The African continent, with its genetically diverse populations, is a treasure trove of pharmacogenomics data – as long as African patients are included in drug studies, as we discussed in this Uppsala Reports Long Read episode.As a past member of the European Medicines Agency's Pharmacogenomics Working Party, Ying contributed to the “Guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products”.Ying also chairs ISoP's Pharmacogenomics Special Interest Group, whose work and objectives have been described in Uppsala Reports and Drug Safety. Join the conversation on social mediaFollow us on Twitter, Facebook or LinkedIn, and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to make medicines safer for patients.
Commentary by Dr. Valentin Fuster
Episode #013 This episode is an extension of ACS Part One and focuses on Diagnostics, Drug Therapy and Complications.Follow me on Facebook where you can find daily CCRN Questions! @KayhoppepresentsPlease remember to head over to my website and subscribe to get notices of upcoming podcasts and events! http//:www.kayhoppepresents.comFeel free to contact me for an in-person or online CCRN Review for your facility or nursing group! http://kay@kayhoppepresents.comHave a blessed day!Kay :)
Vice President Harris In Guatemala to Discuss Migration Crisis Root Causes . Department of Justice Announces It's Recovered Cyber Ransom Payment. Indian Capital Begins Reopening Amid Falling Coronavirus Cases. FDA Approves First Alzheimer's Drug Therapy in Decades. The post The Pacifica Evening News, Weekdays – June 7, 2021 appeared first on KPFA.
Achalji is a pioneer in bringing Yoga to a studio setting with his Yoga House, a first-of-its-kind Yoga studio in Mumbai. Achalji is CEO of Greenway Grameen Infra, a social cause initiative to bring safe cooking stoves to rural India. An IIM graduate, Achalji has held senior management positions in Fortune 500 companies such as GE, Sony, and Pepsi. Achalji is also the owner of two acclaimed Yoga eco-retreats in the Pench Tiger Reserve that have won Tripadvisor Travel Choice awards. In this talk, he discusses many of the healings he has witnessed in his 30-year journey as a Yoga Acharya. www.greenwayappliances.com Instagram: @achalmehra Please rate the podcast and reach out if you have any thoughts for me. To leave me a voice message, click here: https://anchor.fm/salila-sukumaran/message --- Send in a voice message: https://anchor.fm/salila-sukumaran/message
Show Notes for Episode Fifteen of seX & whY: Sex Differences in Immunology and Drug Therapy Host: Jeannette Wolfe Guests: Evelyne Bischof MD, Associate Professor of Medicine at Shanghai University of Medicine and Health Sciences and internist at University Hospital of Basel Switzerland Sabra Klein, PhD, Professor of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health This podcast focused on sex differences in immunology and pharmacology and its relevance to the Covid-19 pandemic. Key points Males are more likely to be admitted to the ICU and die from COVID-19 compared to females Males and females have differences in both innate and adaptive immunity (which likely are a combo of chromosomal, hormonal and epigentic differences) One difference in Innate immunity (the initial non-specific reaction to a foreign pathogen) is Toll-like receptor 7 (TLR7) This is a major player in the initial physiological response to a foreign pathogen and the gene for it is on the X chromosome. X-lined genes (like Ace-2 which is the receptor which SARS-Cov-2 initially binds to in the body) are interesting because they immediately bring up two considerations. First, if someone has a specific variant of that gene, it could change their susceptibility to certain pathogens. Males, as they have an XY pair of sex chromosomes, only have one X chromosome and thus could be more adversely impacted than females (XX) who have a second copy of the gene (which may or may not express the same variant) from their other X chromosome. The second consideration is that in the cells of most females, one of the X chromosomes is automatically turned off (X inactivation). It appears however, that some X-linked immune cells- like TLR7- don't do this, leading to the possibility of increased expression of the gene like getting an “extra dose”. In adaptive immunity (which involved B and T cells), females generally have a greater immunological response to most pathogens. As such, females generally exhibit a more robust immune response to natural infections and vaccinations. The flip side, however, is compared to men, women are also at greater risk for autoimmune diseases and are more likely to get local and systemic reactions after a vaccination. When testing the effectiveness and side effects of SARS-CoV-2 vaccines it would be ideal to consider the variables of biological sex and age. In an influenza study, when women were given a ½ dose of the flu vaccine, they mounted a similar immune response to males who got full dose. If the same held true for developing SARS-Cov2 vaccinations, it could potentially increase the amount of vaccine available (though it is unclear if this is even being considered in early vaccine trials). Aging can also impair the immune response and older adults may require higher doses of booster doses of some vaccines to optimize their immune response The use of Artificial Intelligence in drug development may revolutionize the pharmaceutical research industry by allowing more predictive drug modeling leading to more successful drug development. This could also be used to better identify potentially important biological sex- based pharmacodynamic and pharmacokinetic differences earlier in drug development. Two unexpected findings associated with COVID-19 Males appear to be more vulnerable to cytokine storm (mechanism still not entirely clear may be differences in ACE-2 receptors, or chromosomal/hormonal differences in innate/adaptive immune system) Elderly sick males who survived COVID-19 appear to have significant protective antibody production against SARS-Cov2 References: Bischof E, Wolfe J, Klein S: Clinical trials for Covid-19 should include Sex as a Variable. JCI 2020 Engler R, Nelson M, Klote M, et al. Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005) Age, Dose, and Sex Effects on Immune Responses, JAMA Internal Medicine 2008 Gender and COVID-19 Working Group website Global Health 50/50 global deaths disaggregated by sex Klein S, Pekosz A, Park H. et al. Sex, age and hospitalization drive antibody responses in a Covid-19 convalescent plasma donor population. JCI 2020 Roberts M, Genway S How Artificial Intelligence is transforming drug design. DDW Souyris M, Cenac C, Azar P, et al. TLR7 Escapes X Chromosome Inactivation in Immune Cells. Autoimmune Disease 2018 Takehiro T, Ellingson M, Wong P et al. Sex Differences in Immune Responses that underlie COVID-19 disease outcomes. Nature 2020 Zucker I, Prendergast B. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences 2020 Special thanks to Doug Deems for help with editing
Dr Betty Eisner's Drug Therapy CultIn this episode, Tory sits down to chat with me about her time within Dr Betty Gover Eisner's community that she ran using cult methods of control. Eisner pioneered LSD research and other drugs from the 50's, 60's, 70's and eventually lost her license after the death of a participant in a drug therapy session.Get In TouchInstagram: https://www.instagram.com/cultvaultpod/Twitter: https://twitter.com/CultVaultPodTumblr: https://www.tumblr.com/blog/cultvaultReddit: https://www.reddit.com/user/Cult-VaultGmail: cultvaultpodcast@gmail.comPatreon: https://www.patreon.com/thecultvaultSourceshttps://en.wikipedia.org/wiki/Betty_Eisnerhttps://maps.org/images/pdf/books/remembrances.pdfhttps://yorkspace.library.yorku.ca/xmlui/bitstream/handle/10315/34493/Davidson_Tal_2017_Masters.pdf?sequence=2&isAllowed=ySupport this podcast at — https://redcircle.com/cultvaultpodcast/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
The patient standing at the pharmacy to fill a prescription represents the "final mile" that started in the laboratory. All the science and commercial investment comes down to this one decision point. Will the patient walk away? What will get them to stay? In a survey of 200,000 retail prescriptions for the top 100 branded oral drugs, two inVentiv companies - Adheris Health and inVentiv Health Consulting - set out to understand the most influential factors to driving patient adherence or non-adherence. Jeff Stewart sits down with Linda Morini, Senior Director, Analytic Services and Mike Occhipinti, Vice President, Analytics at Adheris Health, to discuss what they found. Interested in learning more about the complex issue of adherence? Check out the inVentiv Health Communications white paper on social centricity, which discusses social forces that shape patient decisions. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.
© 2020-2025 Ivy Podcast Discovery LLC
